Publications

BibTex format

@article{Gnanenthiran:2021:10.1136/bmjopen-2020-043625,
author = {Gnanenthiran, SR and Borghi, C and Burger, D and Charchar, F and Poulter, NR and Schlaich, MP and Steckelings, UM and Stergiou, G and Tomaszewski, M and Unger, T and Wainford, RD and Williams, B and Rodgers, A and Schutte, AE},
doi = {10.1136/bmjopen-2020-043625},
journal = {BMJ Open},
pages = {1--7},
title = {Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension},
url = {http://dx.doi.org/10.1136/bmjopen-2020-043625},
volume = {11},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Introduction Whether ACE inhibitors (ACEi) or angiotensin II receptor blocker (ARB) therapy should be continued, initiated or ceased in patients with COVID-19 is uncertain. Given the widespread use of ACEi/ARBs worldwide, guidance on the use of these drugs is urgently needed. This prospective meta-analysis aims to pool data from randomised controlled trials (RCTs) to assess the safety and efficacy of ACEi/ARB therapy in adults infected with SARS-CoV-2.Methods and analysis RCTs will be eligible if they compare patients with COVID-19 randomised to ACEi/ARB continuation or commencement versuss no ACEi/ARB therapy; study duration ≥14 days; recruitment completed between March 2020 and May 2021. The primary outcome will be all-cause mortality at ≤30 days. Secondary outcomes will include mechanical ventilation, admission to intensive care or cardiovascular events at short-term follow-up (≤30 days) and all-cause mortality at longer-term follow-up (>1 month). Prespecified subgroup analyses will assess the effect of sex; age; comorbidities; smoking status; ethnicity; country of origin on all-cause mortality. A search of ClinicalTrials.gov has been performed, which will be followed by a formal search of trial registers, preprint servers, MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials to identify RCTs that meet inclusion criteria. To date, a search of ClinicalTrials.gov identified 21 potentially eligible trials for this meta-analysis. We will request trial investigators/sponsors to contribute standardised grouped tabular outcome data.Ethics and dissemination Ethics approval and informed consent will be the responsibility of the individual RCTs. Dissemination of results will occur by peer-reviewed publication. The results of our analysis can inform public health policy and clinical decision making regarding ACEi/ARB use in patients with COVID-19 on a global scale.
AU  - Gnanenthiran,SR
AU  - Borghi,C
AU  - Burger,D
AU  - Charchar,F
AU  - Poulter,NR
AU  - Schlaich,MP
AU  - Steckelings,UM
AU  - Stergiou,G
AU  - Tomaszewski,M
AU  - Unger,T
AU  - Wainford,RD
AU  - Williams,B
AU  - Rodgers,A
AU  - Schutte,AE
DO  - 10.1136/bmjopen-2020-043625
EP  - 7
PY  - 2021///
SN  - 2044-6055
SP  - 1
TI  - Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension
T2  - BMJ Open
UR  - http://dx.doi.org/10.1136/bmjopen-2020-043625
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000621082800009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://bmjopen.bmj.com/content/11/2/e043625
UR  - http://hdl.handle.net/10044/1/88012
VL  - 11
ER  -

Download

Professor Neil Poulter

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)